At bronchial asthma leykotriyenoposredovanny effects start the bronchospasm mechanism, the phlegm is allocated, passability of bronchial tubes decreases and the quantity of eosinophils increases. Montelukast – active connection, contacts sharp selectivity with Syslt1-retseptorami, becomes the reason of blocking of tsisteinilleykotriyenovy receptors in a respiratory organs, it is caused by ability of drug to inhibit a bronkhokonstriktion at people with bronchial asthma. Even small doses in 5 mg considerably block the bronkhokonstriktion caused by LTD4. After peroral acceptance of drug there is a bronkhodilatation which lasts about two hours.

Thus, as show responses, Singulyar can suppress a bronchospasm at any stages, both on early, and on late, lowering reaction to antigens.

Pharmacokinetics

After reception Singulyar is quickly soaked up by an organism. At acceptance of one tablet on an empty stomach by the adult, fixes achievement of the maximum concentration in blood in 3 hours. Bioavailability of substance makes 64%. Efficiency and safety were confirmed during clinical tests in groups which took a pill coated on 10 mg, irrespective of food. About 99% of drug contact proteins of plasma. As well as its analogs Singulyar is actively metabolized. Researches showed that the role of metabolites in therapeutic effect Singulyara is minimum.

At reception orally of Singulyar's dose, marked isotope, established removal of 86% with a stake within five days and about 0,2% with urine. This fact says that metabolites are removed almost completely with bile.

Singulyar's reception in doses at 20-60 times exceeding recommended shows decrease in theophylline in a blood plasma. However the similar effect is not observed at reception of usual doses of not exceeding 10 mg a day.

Indications to Singulyar's use

Tablets with a cover: for adults and children of 15 years, according to the instruction, Singulyar can is applied as auxiliary treatment of persistent bronchial asthma of different forms of the weight which is badly controlled by inhalation glucocorticosteroids or agonists of adrenoceptors and also to treatment of seasonal rhinitis of an allergic origin at patients with bronchial asthma.
Also as prevention of the asthmatic attack caused by exercise stresses.

Chewable tablets Singulyar:

are written out to children from 2 to 15 years as auxiliary treatment of persistent asthma of various degrees of severity;
as an alternative to treatment by low doses of inhalation glucocorticosteroids at an easy form of asthma;
in case of intolerance of inhalers, as prevention before exercise stresses for patients with bronchial asthma.

Application instruction of Singulyar

Tablets, coated. To children of 15 years and the adult, one tablet (10 mg) a day.

Chewable tablets. To children of 2-15 years to apply only under observation of adults.
Children of younger age from 2 to 5 years receive 1 tablet of Singulyar (4 mg), once a day - in the evening for an hour before meal, or in two hours later. Children from 6 to 14 years receive 1 tablet (5 mg) once in the evening for an hour before meal, or in two hours later. Need of individual selection of a dose is absent. Сингуляр 10 мг

Contraindications to Singulyar's use

High sensitivity to drug components.
To children up to 2 years, in any kind.
To children up to 15 years, a tablet coated.
Pill of 10 mg is taken only after consultation with the doctor.

Side effects

Are possible: a headache, an abdominal pain, the raised bleeding, an anaphylaxis, dizziness, hypotension, tachycardia, diarrhea, dyspepsia, dryness in a mouth, vomiting and nausea, a sleep disorder, nightmares, hallucinations, irritability, sleeplessness, excitement, an agressive behavior, a depression, a tremor, spasms, it is extremely rare – thirst for a suicide. Skin manifestations in the form of rash, a small tortoiseshell, hematomas, hypostases are possible.

Special instructions

Singulyar does not stop asthmatic attacks, for this purpose it is necessary to use the corresponding drugs. Also it is not recommended to pass sharply from inhalation or peroral corticosteroids and their analogs on Singulyar. The therapeutic effect of Singulyar concerning control of an attack of asthma works during the day. Unlike analogs, Singulyar is accepted without binding to meal. It is recommended not to interrupt Singulyar's reception even at aggravations, or transition of bronchial asthma to a controlled stage. Correction of doses for elderly patients and patients with a liver or renal failure benign is not required.

Singulyar can be addition to inhalation glucocorticosteroid therapy.

Pregnancy and feeding by a breast

There are no enough practical reviews of Singulyar as means of therapy at pregnancy and a lactation therefore at appointment it is necessary to commensurate advantage for mother and possible harm for the child.

There are no these researches about Singulyar's penetration into breast milk therefore at use it is also necessary to consider a ratio of advantage and risk.

Singulyar's influence on concentration and ability to manage vehicles, however at some patients is not established, during reception there can be a drowsiness and dizziness in this connection will better refrain from management of transport during therapy.

Overdose by Singulyar

There is no information on overdose at treatment by Singulyar. In most cases Singulyar's overdoses responses demonstrate that no side effects are observed. In certain cases the abdominal pain, thirst, drowsiness, vomiting, a headache, a hyperactivity can become result of overdose.

In Singulyar's instruction there are no data on a possibility of removal of drug through peritoneal dialysis or a hemodialysis.